15 reports

  • STATINS
  • INCREASING USE OF STATINS

You can easily book an appointment with one online.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • STATINS
  • STATINS

The prevalence rate for FH ranges between one in ## to one in ## people.

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • PATENT ANALYSIS FOR GLOBAL DULOXETINE & ATORVASTATIN DRUGS
  • Untitled

Merck and Bristol-Myers Squibb already had established statins in the market.

  • Statins
  • North America
  • United States
  • World
  • Market Shares
  • Target
  • Clinical Trial profile. 513 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • Mar 13, 2019: New cholesterol-lowering drug could help patients unable to take statins
  • BEMPEDOIC ACID - DRUG PROFILE

Among the completed Phase III trials, in study ## (patients with ASCVD on MTD statin), bempedoic acid ##mg lowered LDL-C by ## percent.

  • Chronic Disease
  • Statins
  • United States
  • Company
  • Amarin Corporation plc

Part ##.

  • Clinical Trial
  • Drug Development
  • Statins
  • World
  • Merck & Co., Inc.
  • Official Title

Part ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Statins
  • World
  • Merck & Co., Inc.
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns
  • May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia

Liptruzet contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin, currently one of the most widely prescribed statins in the US.

  • Lipid Modifying Drug
  • Statins
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Target
  • Target

The prominent features of this report are - ##.

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns
  • May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia

Niemann Pick C## Like Protein ## (NPC##L##) - Dormant Projects When using ZETIA with a statin, also follow the label recommendations for that specific statin.

  • Lipid Modifying Drug
  • Statins
  • United States
  • World
  • Product Initiative

It also does belong to the group of medicines known as statins, which is also known as the HMG-CoA reductase inhibitors.

  • Pharmaceutical
  • Statins
  • Therapy
  • United States
  • World
  • Target
  • Official Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Statins
  • World
  • Product Initiative
  • Mar 18, 2017: No Benefit of Synthetic HDL-C on Arterial Plaque
  • ATHEROSCLEROSIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*

In the E. U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach th

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • most common adverse events (AEs) in this trial were nasopharyngitis, injection-site reaction and headache.

One arm of the study will focus on evaluating the effect of CAT-2003 on lipid levels in combination with statins in patients with hypercholesterolemia.

  • Endocrine Disease
  • Statins
  • United States
  • Company
  • Product Initiative